RIBOLIFE-B (06938) rose more than 5%, reaching a gain of 5.62% to HK$72.45 by the time of writing, with a turnover of HK$6.483 million. The increase follows the company's recent announcement that its self-developed RBD5044 injection has received implied approval from China's National Medical Products Administration for Phase II clinical trials. RBD5044 is an siRNA drug targeting APOC3, a protein synthesized almost exclusively in the liver that plays a key role in lipid metabolism. The drug is designed to address complications associated with hypertriglyceridemia, offering a potential treatment option for managing dyslipidemia. Industry analysts suggest that small nucleic acid drugs are entering a period of rapid global growth, transitioning from the technology validation phase to accelerated clinical and commercial development. Currently, 23 small nucleic acid drugs have been approved worldwide, covering multiple technological approaches such as siRNA, ASO, and aptamers. Although no products have been launched domestically yet, China's R&D pipeline ranks second only to the United States, spanning therapeutic areas including hyperlipidemia, hypertension, hepatitis B, kidney disease, muscular disorders, and obesity. Significant international collaborations, such as Bowang Pharmaceutical's cumulative deals with Novartis exceeding $9 billion and RIBOLIFE-B's platform licensing agreement with Boehringer Ingelworth up to $2 billion, highlight the sector's positive momentum. Traditional pharmaceutical companies like Sino Biopharmaceutical are also rapidly entering the field through acquisitions.